Skip to content
Homepage

Semaglutide: Ozempic, Wegovy and Rybelsus Explained

Used by 882 clinics in our directory

Semaglutide is a prescription GLP-1 receptor agonist made by Novo Nordisk. In the US it is sold as Ozempic (weekly injection or daily tablet), Wegovy (weekly injection or daily tablet) and Rybelsus (daily tablet), each with its own FDA-approved uses [1][2][3].

The Ozempic label describes semaglutide as "a GLP-1 analogue with 94% sequence homology to human GLP-1" that binds to and activates the GLP-1 receptor, with an elimination half-life of "approximately 1 week" [1]. This page covers the brand-name drug: what each label approves, how each form is given, what the pivotal trials measured, what it costs, and how to find and check a clinic that prescribes it.

Sources checked November 20, 2026.

What is semaglutide?

Semaglutide is the active ingredient in three Novo Nordisk brands: Ozempic, Wegovy and Rybelsus. All three US labels name Novo Nordisk Pharmaceutical Industries, LP and list an initial US approval of 2017 for the molecule [1][2][3]. Each label calls the product a glucagon-like peptide-1 (GLP-1) receptor agonist.

According to the Ozempic label, semaglutide "stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner," and its blood-sugar effect "also involves a minor delay in gastric emptying in the early postprandial phase" [1]. The label attributes its long half-life mainly to albumin binding and states that, with an elimination half-life of about one week, "semaglutide will be present in the circulation for about 5 weeks after the last dose" [1].

The brand name matters because each brand carries its own approved uses, doses and price. A prescription for Ozempic is not a prescription for Wegovy, even though the molecule is the same.

What is semaglutide FDA approved for?

The approved uses below are copied from the current labels on DailyMed: Ozempic injection (version effective June 2026), Wegovy injection and tablets (revised June 2026) and the combined Rybelsus and Ozempic tablets label (revised January 2026, posted to DailyMed in August 2026) [1][2][3].

Ozempic injection

The label states Ozempic is indicated [1]:

  • "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus"

  • "to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease"

  • "to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease"

Wegovy injection

The label states Wegovy injection is indicated "in combination with a reduced calorie diet and increased physical activity" [2]:

  • "to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight"

  • "to reduce excess body weight and maintain weight reduction long term" in "adults and pediatric patients aged 12 years and older with obesity" and in "adults with overweight in the presence of at least one weight-related comorbid condition"

  • "for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)" with "moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults"

The label notes that the MASH indication "is approved under accelerated approval based on improvement of MASH and fibrosis" and that "continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial" [2].

Wegovy tablets

Wegovy tablets share the cardiovascular risk-reduction indication and the weight indication for adults with obesity, or with overweight plus at least one weight-related condition. The tablet label does not include the pediatric or MASH indications [2]. The label also states that using Wegovy "with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended" [2].

Rybelsus and Ozempic tablets

Rybelsus and Ozempic tablets share one label. Both are indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" and "to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events" [3]. The label states the two tablets "are not substitutable on a mg-to-mg basis" [3].

  • Ozempic injection: How often: Once weekly; Labeled uses (summary): Type 2 diabetes glucose control; cardiovascular risk in type 2 diabetes with heart disease; kidney and cardiovascular risk in type 2 diabetes with chronic kidney disease [1]

  • Wegovy injection: How often: Once weekly; Labeled uses (summary): Weight reduction (adults, and ages 12 and up with obesity); cardiovascular risk in adults with heart disease and obesity or overweight; MASH with F2 to F3 fibrosis (accelerated approval) [2]

  • Wegovy tablets: How often: Once daily; Labeled uses (summary): Weight reduction in adults; cardiovascular risk in adults with heart disease and obesity or overweight [2]

  • Rybelsus and Ozempic tablets: How often: Once daily; Labeled uses (summary): Type 2 diabetes glucose control; cardiovascular risk in type 2 diabetes at high risk [3]

How is semaglutide taken?

The labels describe two routes: a weekly injection under the skin and a daily tablet. The schedules below are the labels' own, written for prescribers and shown here as published. They are not a plan for any individual reader.

Weekly injection (Ozempic and Wegovy)

Both injection labels direct once-weekly use "on the same day each week, at any time of day, with or without meals," injected subcutaneously "in the abdomen, thigh, or upper arm" [1][2].

The Ozempic label starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg. It lists maintenance doses of 0.5 mg, 1 mg or 2 mg "based on glycemic control," with a "maximum recommended dosage" of 2 mg once weekly. For the chronic kidney disease indication, the label's maintenance dose is 1 mg once weekly [1]. The label says the escalation is designed "to reduce the risk of gastrointestinal adverse reactions" [1].

The Wegovy injection label's escalation table [2]:

  • 1 to 4: Once-weekly dose on the label: 0.25 mg (starting dose)

  • 5 to 8: Once-weekly dose on the label: 0.5 mg

  • 9 to 12: Once-weekly dose on the label: 1 mg

  • 13 to 16: Once-weekly dose on the label: 1.7 mg

  • 17 onward: Once-weekly dose on the label: Maintenance dose set by indication

For weight reduction in adults, the label lists 1.7 mg or 2.4 mg (recommended) as maintenance, and states that for patients who tolerate 2.4 mg for at least 4 weeks "and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg" once weekly, sold as Wegovy HD [2].

Daily tablet (Wegovy, Ozempic and Rybelsus)

The tablet labels direct one tablet daily "on an empty stomach in the morning with water (up to 4 ounces)," swallowed whole, then a wait of "at least 30 minutes before eating food, drinking beverages or taking other oral medications" [2][3].

  • Wegovy tablets [2]: Days 1 to 30: 1.5 mg; Days 31 to 60: 4 mg; Later steps on the label: 9 mg on days 61 to 90; 25 mg maintenance from day 91

  • Ozempic tablets [3]: Days 1 to 30: 1.5 mg; Days 31 to 60: 4 mg; Later steps on the label: Stay at 4 mg, or 9 mg from day 61 if more glucose control is needed

  • Rybelsus [3]: Days 1 to 30: 3 mg; Days 31 to 60: 7 mg; Later steps on the label: Stay at 7 mg, or 14 mg from day 61 if more glucose control is needed

The Rybelsus and Ozempic tablets label notes that the first-month dose "is not effective for glycemic control" and exists to start the escalation [3]. For dose arithmetic with a prescribed product, see our semaglutide dosage calculator.

What did the semaglutide trials measure?

Four Novo Nordisk-funded trials, all published in the New England Journal of Medicine, underpin the main label indications. Each result below is reported as the paper states it.

  • STEP 1 [4]: Who took part: 1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes; Dose and length: 2.4 mg weekly or placebo, plus lifestyle intervention, 68 weeks; Primary outcome and result: Mean body-weight change -14.9% vs -2.4% with placebo

  • SELECT [5]: Who took part: 17,604 adults aged 45 or older with cardiovascular disease and BMI 27 or more, no diabetes; Dose and length: 2.4 mg weekly or placebo; mean follow-up 39.8 months; Primary outcome and result: Cardiovascular death, heart attack or stroke: 6.5% vs 8.0% (hazard ratio 0.80)

  • SUSTAIN-6 [6]: Who took part: 3,297 adults with type 2 diabetes; Dose and length: 0.5 mg or 1.0 mg weekly or placebo, 104 weeks; Primary outcome and result: Cardiovascular death, heart attack or stroke: 6.6% vs 8.9% (hazard ratio 0.74)

  • FLOW [7]: Who took part: 3,533 adults with type 2 diabetes and chronic kidney disease; Dose and length: 1.0 mg weekly or placebo; median follow-up 3.4 years; Primary outcome and result: Major kidney disease events: hazard ratio 0.76 (331 vs 410 first events)

STEP 1: weight in adults without diabetes

STEP 1 randomly assigned adults 2:1 to semaglutide 2.4 mg or placebo. Its primary estimand assessed effects "regardless of treatment discontinuation or rescue interventions." At week 68, mean weight change was -14.9% with semaglutide and -2.4% with placebo, an estimated difference of -12.4 percentage points. A 15% or greater reduction was reached by 50.5% of the semaglutide group and 4.9% of the placebo group [4]. Discontinuation because of gastrointestinal events was 4.5% versus 0.8% [4].

SELECT: heart outcomes in adults with obesity or overweight

SELECT was an event-driven trial in people with existing cardiovascular disease and no history of diabetes. A primary event (cardiovascular death, nonfatal heart attack or nonfatal stroke) occurred in 569 of 8,803 participants on semaglutide (6.5%) and 701 of 8,801 on placebo (8.0%), hazard ratio 0.80 [5]. Adverse events leading to permanent discontinuation were recorded in 16.6% versus 8.2% [5].

SUSTAIN-6: heart outcomes in type 2 diabetes

SUSTAIN-6 was designed to test noninferiority against placebo on cardiovascular events. The primary outcome occurred in 6.6% of the semaglutide group and 8.9% of the placebo group, hazard ratio 0.74 [6]. The paper also recorded higher rates of retinopathy complications in the semaglutide group (hazard ratio 1.76) [6], which is why the Ozempic label lists diabetic retinopathy complications among its warnings [1].

FLOW: kidney outcomes in type 2 diabetes with chronic kidney disease

FLOW was stopped early after a prespecified interim analysis. The primary composite (kidney failure, a 50% or greater fall in eGFR, or death from kidney or cardiovascular causes) had a hazard ratio of 0.76 for semaglutide versus placebo. Death from cardiovascular causes had a hazard ratio of 0.71 [7].

The MASH trial on the Wegovy label

The Wegovy label describes Study 11, an 800-patient biopsy analysis at week 72 in adults with F2 or F3 fibrosis. Resolution of steatohepatitis without worsening fibrosis was recorded in 63% on Wegovy and 34% on placebo; fibrosis improvement without worsening steatohepatitis in 37% and 22% [2].

What is the boxed warning on semaglutide?

All three labels carry the same boxed warning, titled "WARNING: RISK OF THYROID C-CELL TUMORS." The Ozempic label states [1]:

"In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined."

The box continues: "OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)" [1]. The Wegovy and the Rybelsus and Ozempic tablets labels use the same wording with their own brand names [2][3]. Each label's full warnings section lists further precautions, including acute pancreatitis [1].

How much does semaglutide cost?

Prices below are Novo Nordisk's own self-pay prices through NovoCare home delivery or its savings offer, as listed on November 20, 2026. Novo Nordisk states it may change or cancel these programs at any time [8][9]. For a longer comparison, see our semaglutide cost guide.

  • Wegovy pen, new patients: NovoCare self-pay price per month: $199 for each of the first 2 monthly fills of 0.25 mg or 0.5 mg, offer through December 31, 2026 [8]

  • Wegovy pen 0.25 mg to 2.4 mg: NovoCare self-pay price per month: $349 [8]

  • Wegovy HD pen 7.2 mg: NovoCare self-pay price per month: $399 [8]

  • Wegovy tablets: NovoCare self-pay price per month: $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) [8]

  • Ozempic pen, new patients: NovoCare self-pay price per month: $199 for each of the first 2 monthly fills of 0.25 mg or 0.5 mg, offer through December 31, 2026 [8]

  • Ozempic pen 0.25 mg, 0.5 mg or 1 mg: NovoCare self-pay price per month: $349 [8]

  • Ozempic pen 2 mg: NovoCare self-pay price per month: $499 [8]

  • Ozempic tablets: NovoCare self-pay price per month: "Starting at $149," varies by dose [8]

NovoCare defines one month of Wegovy as "1 box of 4 pens" or "1 bottle of 30 tablets," and one month of Ozempic pen as "1 box of 1 Ozempic pen" [8].

Does insurance cover semaglutide?

Coverage depends on the plan and the indication. Novo Nordisk's savings offer lets people with commercial insurance "pay as little as $25" a month, "subject to a maximum savings of $100/month," with government beneficiaries excluded [8][9]. NovoCare notes that money spent on a self-pay purchase outside insurance does not count toward a plan's out-of-pocket limits or deductible [8].

Does Medicare cover Wegovy?

CMS runs the Medicare GLP-1 Bridge, which it calls "a short-term demonstration" giving eligible Part D beneficiaries access to certain GLP-1 drugs "between July 1, 2026, and December 31, 2027," with "a $50 copay" [11]. Novo Nordisk states the $50 Wegovy price under the Bridge applies to "adult patients with Medicare prescribed Wegovy for weight loss only," with eligibility set by CMS [9].

Is the list price changing?

On February 24, 2026, Novo Nordisk announced a "new, lower list price of $675 per month across Wegovy, Ozempic, and Rybelsus," effective January 1, 2027, which it describes as reductions of "approximately 50% and 35%" for Wegovy and Ozempic from the current list price. The company stated that "these changes in list price do not have an impact on direct-to-patient, self-pay prices" [10].

Is compounded semaglutide the same as brand semaglutide?

No. The FDA states that "compounded drugs are not FDA approved" and that it "does not review compounded drugs for safety, effectiveness or quality before they are marketed" [12]. The FDA also announced on February 21, 2025 that "the shortage of semaglutide injection products" was resolved, which changed the rules for pharmacies that had been compounding it [13]. The ingredients, rules and studies of compounded versions are covered on our compounded semaglutide page.

How to find a clinic that prescribes semaglutide

Regenerated.com lists 596 clinics whose own websites name semaglutide as a service, checked November 20, 2026. You can browse them in our directory of semaglutide clinics. A listing means the clinic's website names the service; it is not an endorsement and does not confirm which brand or form the clinic prescribes.

What to ask a clinic before your first visit

  • Which product will be prescribed: Ozempic, Wegovy or Rybelsus by brand, or a compounded preparation? Each has a different label, and compounded products are not FDA approved [12].

  • For which indication? The brand determines the approved use: type 2 diabetes for Ozempic and Rybelsus, weight, heart risk or MASH for Wegovy [1][2][3].

  • Who is the prescriber, and in which states are they licensed?

  • Which pharmacy fills the prescription, and can you use your own pharmacy or NovoCare home delivery [8]?

  • What follow-up and lab monitoring does the clinic include, and what does each visit cost on top of the medicine?

  • Does the clinic check personal and family history of medullary thyroid carcinoma and MEN 2, which the labels list as contraindications [1]?

How to check a prescriber's license

The Federation of State Medical Boards runs DocInfo (docinfo.org), which it describes as "free to the public" and as its "national database of consolidated physician licensure and disciplinary information" [16]. The FSMB also notes that patients can get this information "directly from their state medical board" [16]. For nurse practitioners and physician assistants, the state board that licensed them keeps the record.

How to check the pharmacy

The FDA calls checking a pharmacy's license through your state board of pharmacy "an important step" and says, "If your online pharmacy is not listed, you should not use that pharmacy." A listed pharmacy should also require a prescription, give a US address and phone number, and have "a licensed pharmacist to answer your questions" [15]. After counterfeit Ozempic pens were found in the US supply chain, the FDA advised that patients "should only obtain Ozempic with a valid prescription through state-licensed pharmacies" and check the product for signs of counterfeiting [14].

Related reading

Frequently asked questions

The questions patients ask most before starting Semaglutide.

Semaglutide is the active ingredient; Ozempic is one of Novo Nordisk's brand names for it. Wegovy and Rybelsus contain the same molecule but carry different FDA-approved uses and doses [1][2][3]. Ozempic injection is labeled for adults with type 2 diabetes, while Wegovy is labeled for weight reduction, cardiovascular risk reduction and MASH [1][2].

Both are once-weekly semaglutide injections. Ozempic's label covers glucose control, cardiovascular risk and kidney risk in adults with type 2 diabetes, with a maximum labeled dose of 2 mg weekly [1]. Wegovy's label covers weight reduction in adults and ages 12 and up with obesity, cardiovascular risk in adults with heart disease and obesity or overweight, and MASH with F2 to F3 fibrosis, with a usual maintenance dose of 2.4 mg and a maximum of 7.2 mg weekly for adult weight reduction [2].

Yes. Rybelsus and Ozempic tablets are once-daily semaglutide tablets labeled for adults with type 2 diabetes [3], and Wegovy tablets are a once-daily tablet labeled for weight reduction and cardiovascular risk reduction in adults [2]. The labels direct taking the tablet on an empty stomach with up to 4 ounces of water and waiting at least 30 minutes before eating, drinking or taking other oral medicines [2][3].

Through NovoCare, Novo Nordisk lists Wegovy pens at $349 a month for doses up to 2.4 mg and $399 for the 7.2 mg Wegovy HD pen, Wegovy tablets at $149 to $299 depending on dose, and Ozempic pens at $349 (up to 1 mg) or $499 (2 mg), as checked November 20, 2026. New patients pay $199 for each of the first two monthly fills of the 0.25 mg or 0.5 mg pens through December 31, 2026 [8].

Through the CMS Medicare GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027, eligible Part D beneficiaries have "a $50 copay" for certain GLP-1 drugs [11]. Novo Nordisk states the $50 Wegovy price applies to "adult patients with Medicare prescribed Wegovy for weight loss only," with eligibility determined by CMS [9].

The Ozempic label gives an elimination half-life of approximately one week and states that "semaglutide will be present in the circulation for about 5 weeks after the last dose" [1].

References

1. Novo Nordisk, OZEMPIC (semaglutide) injection, for subcutaneous use: prescribing information, DailyMed label version effective June 1, 2026

2. Novo Nordisk, WEGOVY (semaglutide) injection and tablets: prescribing information, revised June 2026 (DailyMed)

3. Novo Nordisk, RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information, revised January 2026, posted to DailyMed August 19, 2026

4. Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), N Engl J Med, March 18, 2021

5. Lincoff AM et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), N Engl J Med, December 14, 2023

6. Marso SP et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6), N Engl J Med, November 10, 2016

7. Perkovic V et al., Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW), N Engl J Med, July 11, 2024

8. Novo Nordisk, NovoCare home delivery: Wegovy and Ozempic self-pay pricing, accessed November 20, 2026

9. Novo Nordisk, NovoCare: Wegovy savings offer and Medicare GLP-1 Bridge pricing, accessed November 20, 2026

10. Novo Nordisk, Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus semaglutide medicines, February 24, 2026

11. Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge, page modified July 13, 2026

12. US Food and Drug Administration, FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of October 1, 2026

13. US Food and Drug Administration, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, content current as of April 1, 2026

14. US Food and Drug Administration, FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in US drug supply chain, content current as of December 5, 2025

15. US Food and Drug Administration, BeSafeRx: Locate a state-licensed online pharmacy, content current as of November 13, 2024

16. Federation of State Medical Boards, Guide to medical regulation in the United States: Information for consumers (archived March 3, 2021)